US FDA approves Daiichi Sankyo's Benicar for paediatric hypertension
This article was originally published in Scrip
Executive Summary
The US FDA has given Daiichi Sankyo the green light to market its drug Benicar (olmesartan medoxomil) for hypertension in paediatric patients aged 6-16. The angiotensin II receptor antagonist was approved in the US for hypertension in adults in 2002.